CureVac (NASDAQ:CVAC - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $3.58, but opened at $3.83. CureVac shares last traded at $3.61, with a volume of 219,869 shares trading hands.
CureVac Trading Down 0.5 %
The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average price of $3.59 and a 200 day moving average price of $3.21. The stock has a market capitalization of $817.16 million, a PE ratio of 6.64 and a beta of 2.51.
Institutional Investors Weigh In On CureVac
Institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC bought a new position in shares of CureVac in the third quarter worth $30,000. Integrated Wealth Concepts LLC bought a new stake in CureVac in the third quarter valued at approximately $35,000. International Assets Investment Management LLC purchased a new position in shares of CureVac in the third quarter worth $35,000. Jump Financial LLC bought a new stake in shares of CureVac in the fourth quarter worth about $55,000. Finally, Barclays PLC bought a new position in shares of CureVac during the third quarter valued at approximately $67,000. 17.26% of the stock is owned by hedge funds and other institutional investors.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
